Beneficial effects of celery seed extract (Apium graveolens), as a supplement, on anxiety and depression in hypertensive patients: a randomized clinical trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

The current study has investigated the effects of celery seed extract, as a drug supplement, with the active ingredient of 3-n-butylphthalide, on mental problems primarily anxiety and secondary depression in hypertensive patients.

Why It Was Studied

Anxiety and depression can worsen hypertension and vice versa.

Registry name: Iranian Registry of Clinical Trials (IRCT), Registration number: IRCT20130418013058N8, Registration link: https://www.irct.ir/trial/30021.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and crossover study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

The current study was a randomized, triple-blind, placebo-controlled, cross-over, 4-week clinical trial with a 4-week washout period.

The blood pressure parameters were assessed using 24-h ambulatory blood pressure monitoring device.

Anxiety and depression and their wide range of symptoms were evaluated using Beck anxiety and depression inventories (BAI and BDI).

What Was Measured

Topics PubMed links to this paper include Apium, Depression, Blood Pressure Monitoring, Ambulatory, Iran, Anxiety, Hypertension and Plant Extracts.

Author keywords: Celery capsules, Cross-over clinical trial, Herbal medicine and Hypertensive patients.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Copper (Supplement).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Inflammopharmacology), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.